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Abstract
Background and objectives: Methotrexate (MTX) is globally used by physicians to treat patients with Rheumatoid
Arthritis (RA). Previously conducted researches indicate prevalent side effects associated with conventional once-weekly
dosage amongst a population sample of patients consuming MTX. The objectives of our study were to ﬁnd out whether
there is a difference between the two studied regimens in efﬁcacy and adverse effects of methotrexate.
Materials and methods: Study participants were recruited from the outpatient rheumatology department after ethical
approval and informed patient consent. Disease activity was assessed at baseline with various reliable and validated
scales (SDAI, PAS, DAS-28 among others) after the propensity score-matched 1:1 among the two groups. One group
continued their once-weekly regimen (group A), while the other group had their dosage of oral MTX split into alternate
days per week (group B). The propensity-matched groups of 123 patients each were included in the ﬁnal analysis.
Results: The most frequently reported side effect was decreased appetite, followed by gastritis, nausea, headache, and
vomiting. Within the two groups, no signiﬁcant differences were found in disease activity scales. The only considerable
difference was mean corpuscular volume (MCV) being higher in Group A (p ¼ 0.0128). Comparison of side effect proﬁle
at 6 months after intervention showed improved gastritis (63.4 vs 41.5%), nausea (51.2% vs 35.8%), appetite (74.0% vs
60.2%) and hepatotoxicity (14.6% vs 5.7%) in Group B.
Conclusion: An alternate-day regimen may prove more beneﬁcial to the patient's compliance due to fewer side effects
and similar efﬁcacy to the conventional dosage.
Keywords: Joint, Arthritis, Rheumatoid, Methotrexate, Regimen

1. Introduction

M

ethotrexate (MTX) is a disease-modifying
anti-rheumatoid drug (DMARD). It is globally used by physicians to treat patients with
Rheumatoid Arthritis (RA) apart from its other uses

in many diseases as an immunosuppressant and
chemotherapeutic agent. MTX is engrossed by the
cells of the human body and is transformed into its
active metabolite i.e. polyglutamate, whose half-life
is of 3 days.1 Its anti-inﬂammatory effect is due to invivo formation of the drug's active form which is
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responsible for inhibition of Dihydrofolate reductase and 5-Aminoimidazole 4-carboxamide ribotide.
The latency period of MTX is 4e8 weeks.1,2 MTX
decreases pain and swelling, decelerates joint
damage, and reduces disease activity over time.2 It
can be given in combination with other drugs
including sulfasalazine, hydroxychloroquine, tumor
necrosis factor (TNF) Inhibitors, and biological
agents such as Abatacept, Tocilizumab, etc.2
Commonly prescribed regimen of MTX is a single
oral dose per week but the half-life of its active
compound is 3 days. Once weekly regimen which is
used at present was also validated for the treatment
of Psoriatic arthritis.1 Dosage should be given for at
least 6 months in order to accurately evaluate
treatment efﬁcacy.2 28% higher bioavailability is
observed with splitting dosage as compared to a
single oral dose, resulting in superior drug efﬁcacy.3
Splitting the oral dose is a better option than using
the parenteral route when a substantial dose of MTX
is required to control disease activity.3 The conventional dosage is started with a dose of 7.5 mg/
week, rising every 4e8 weeks up to 25e30 mg/week,
respectively. When MTX dose exceeds 15 mg/week,
oral absorption decreases by 30%, it is then delivered via the parenteral route.3 About 95% of patients
receive MTX orally with a maximum dosage of
15 mg/week.2
Both intramuscular and subcutaneous routes are
suitable for MTX administration. Comparatively,
subcutaneous administration is more suitable as it
causes considerably less pain.4 The administration
of injectable dose increases treatment cost along
with the fact that most patients complain of pain at
the injection site.3 Chronic use of MTX results in the
occurrence of numerous adverse effects. Methotrexate Intolerance Severity Score (MISS) is higher
with parenteral MTX (20.8%) in comparison to oral
MTX use (6.2%). Similarly, patients on parenteral
dosage have more behavioral symptoms (95%)
compared to the ones on the oral route (58.3%).
Skipping of dosage and non-compliance to MTX has
been a factor reported previously in our population
as well as in international studies due to its adverse
events proﬁle.5,6
Rheumatoid Factor (RF) and anti-citrullinated
protein antibodies (Anti-CCP) are associated with
Rheumatoid Arthritis.7 It also involves extra-articular organs including skin, eyes, lungs, heart, kidneys, brain, spinal cord, and intestines. The
presence of radiographic joint damage is suggestive
of a poor prognosis.2,8,9 European League Against
Rheumatism (EULAR) proposed that patients taking
MTX should be given folic acid. It reduces the
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chances of non-compliance and treatment withdrawal by reducing side effects.2,10,11

2. Objectives
The objectives of our study were to ﬁnd out
whether there is an improvement in side effects by
splitting the dosage into two halves on alternate
days without affecting the efﬁcacy of the drug with
optimum disease control. A follow-up period of six
months was observed between the changes in dose
and response measurement.

3. Materials & methods
This study was conducted at the Rheumatology
outpatient department of a tertiary care hospital
after ethical approval was granted by the institutional review board. The study protocol complied
with the Declaration of Helsinki. The study included
patients suffering from RA diagnosed by American
College of Rheumatology (ACR) criteria, who were
already on MTX. A sample size of 120 was calculated
by World Health Organization (WHO) sample size
calculator using the formula (n ¼ z2 1-a/2s2/d2), by
estimating the population means through continuous response variables. The Simpliﬁed Disease
Severity Index (SDAI) score utilized by a previous
study was taken as 20.5 ± 9.2 reported in their patients.3 Absolute precision required was set at 0.165,
conﬁdence interval of 95% and error of margin of
5% gave power of the study as 80.4%. The sampling
was done as non-probability consecutive methods.
The patients included had active synovitis and were
already on oral MTX therapy for at least 3 months
before inclusion in the study, along with low-dose
steroids (<10 mg/day) and non-steroidal anti-inﬂammatory drugs (NSAIDs) if indicated by their
primary physician. Most of the patients were on
hydroxychloroquine as the second DMARD to
control disease activity as indicated by the primary
physician. The excluded patients were those who
were pregnant or had any hepatic or renal derangements or were non-compliant with medication. Patients who previously used other DMARDs
including leﬂunomide or biological agents were
excluded from the study. A total of 399 patients were
initially screened from the inclusion criteria after
excluding the above-mentioned and were obtained
informed consent to participate in the study. After
consent, the patients were initially screened for
skipping of dosage (deﬁned as non-compliance or
irregular dosing lasting for more than 2 weeks
during any time of drug administration for any
period) during their previous MTX dosage. All
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participants were checked for complete blood count,
liver function enzymes, and renal function tests at
baseline. The disease activity was assessed at baseline with various reliable and validated scales. The
participants were classiﬁed into two groups based
on their dosage of oral MTX once weekly or being
split into alternate days per week (half dose on
Sunday and half on Tuesday) along with folic acid
administration on alternate days of MTX administration. Propensity Score for both groups was
matched for similarity of baseline characteristics
adjusted for covariates including age, gender,
duration of RA diagnosis, frequency of dosage at
baseline, duration of MTX use, history of skipped
dosage, RA factor and Anti-CCP positivity, and
other comorbid conditions like diabetes and hypertension, and baseline disease severity scores.
The ﬁnal selection criteria are shown in Fig. 1, with
38 patients excluded from the analysis. The dropout
and other exclusions included 15 more individuals.
Hence, a total of 246 participants completed the
study, 123 being in each group. The patients were
followed-up every month in the rheumatology clinic
and the outcomes were reported after six months of
intervention.
3.1. Statistical methods
All statistical analysis was conducted by Statistical
Package for Social Sciences (SPSS version 25.0) for
Windows (IBM Corp., Armonk, NY). Data were
presented as means and standard deviation, or frequency and percentage. The means and frequencies
reported were compared with the student's t-test,
chi-square, or Fisher's Exact test as indicated when
the expected values in any of the cells of a contingency table are below 5. The normality of data distribution was determined by ShapiroeWilk test. A
p-value of >0.05 was considered to label the data as
normally distributed. While, p-value <0.05 indicates
non-normal distribution. The scales used to assess
the disease activity of RA are listed as follows:

activity, respectively. This index was pioneered by
Dr. Josef Smolen, consultant rheumatologist at the
University of Vienna and Lainz Hospital, Vienna,
Austria. It is approved by both EULAR and ACR
along with WHO.12
3.3. Patient global assessment of disease activity
This scale is also utilized to determine the progress of disease activity, as a component of patient
activity scale II, by asking a single question from
patients about how well they are performing in their
daily life activities (given all the manners in which
the disease affects them). This scale ranges from
0 denoting very well to 10 denoting poor status. This
scale was pioneered by Dr. Frederick Wolfe, a
rheumatologist, and professor of medicine at Kansas
School of Medicine.13
3.4. Physician global assessment
This criterion of assessment is utilized to determine the severity of disease by monitoring daily
reports on the number of joints swollen and tender,
acute phase reactants like erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP), today's function index, pain score, and patient global
score. All recent ﬁndings are compared with baseline ﬁndings and deviations are recorded in numerical percentage form. All these ﬁndings play a
vital role in calculating SDAI scores.14
3.5. Pain visual analogue scale
This scale is also a component of patient activity
scale II, it is utilized to determine the severity of the
pain suffered by individuals suffering from RA. This
scale also helps in determining activity of the disease ranging from 0 being no pain and 10 being the
worst pain one could imagine. This scale also works
on patients' quoted grading of pain. It was also
envisaged by Dr. Frederick Wolfe.13

3.2. Simpliﬁed disease activity index (SDAI)

3.6. Patient activity scale II (PAS-II)

This index utilized in our study determines disease activity in patients with rheumatoid arthritis
with numerical results of ﬁve parameters including
tender and swollen joint count (28 joint assessment),
patient and physician global assessment of disease
activity, and levels of CRP. SDAI index is categorized into four ranges with (< than or equal to 3.3)
indicating remission, (>3.3e11.0) indicating low
disease activity (>11.0e26.0) indicating moderately
debilitating disease while (>26) indicating high

This scale is opted to decipher activity of the disease comprising of two scales (pain visual analogue
scale and patient global assessment of disease activity) including a short questionnaire called health
assessment questionnaire disability index II (HAQ
II). The questionnaire consists of four options
(without any difﬁculty, with some difﬁculty, with
much difﬁculty and inability) as answers to questions regarding daily life activities. The formula to
utilize this parameter of assessment is [PAS¼ (A X
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Fig. 1. Methodology (inclusion/exclusion) criteria of the study participants.

3.33 þ BþC)/3] with A being (HAQ II), B being pain
visual analogue scale and C being patient's global
assessment of disease activity. This scale was also
created by Dr. Frederick Wolfe.13
3.7. Patient activity scale I (PAS-I)
This scale is slightly different than patient activity
scale II with an increased number of questions in the
questionnaire called health assessment questionnaire

disability index I (HAQ I) as compared to HAQ II.
Similarly, two scales are utilized (pain visual analogue
and patient's global assessment of disease activity).
The questionnaire consists of a variety of questions
divided into sets of answers like (without any difﬁculty, with some difﬁculty, with much difﬁculty and
inability), and two sets of yes and no. These questions
are regarding daily life activities, usage of assisted
devices, and seeking help from others to perform
chores. The formula is similar to PAS II (A X
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3.33 þ BþC) with A being HAQ I, B being pain visual
analogue and C being patient's global assessment of
disease activity, respectively.13
3.8. Disease activity score (DAS) 28-CRP
This scale determines the severity of rheumatoid
arthritis by utilizing numbers of tender and swollen
joints, levels of CRP of recent intervals compared
with baseline values in percentages, and global
health scale denoting quality of life at recent intervals
marked on visual analogue scale with 0 being very
poor while 10 being very well. DAS-28 CRP is categorized into 4 ranges with a score of <2.6 rendering
remission, 2.6e3.2 denoting low activity, 3.2e5.1 denotes moderate activity while >5.1 denotes high activity, respectively. Formula of DAS-28 CRP is
[0.56*√(Tender Joint Count) þ0.28*√(Swollen Joint
Count) þ0.7*ln(CRP)þ0.014*(global health)]. This
scale was pioneered by Dr. Jaap Fransen, a senior
researcher in rheumatology and professor of clinical
research at Radboud University, Netherlands.15
3.9. Disease activity score (DAS) 28-ESR
This scale determines the severity of rheumatoid
arthritis by utilizing numbers of tender and swollen
joints, levels of ESR of recent intervals compared
with baseline values in percentages, and global
health scale denoting quality of life at recent intervals marked on visual analogue scale with
0 being very poor while 10 being very well. DAS-28
ESR is categorized similarly into 4 ranges as with
DAS-28 CRP. The formula of DAS-28 ESR is
[0.56*√(Tender Joint Count) þ0.28*√(Swollen Joint
Count)þ0.7*ln(ESR)þ0.014*(global health)]. This
scale was also pioneered by Dr. Jaap Fransen.15
3.10. ACR 20 criterion
This criterion is used to assess the improvement
in the number of tender and swollen joints and
improvement in three out of ﬁve constituents 1)
acute phase reactants, 2) patient global assessment,
3) physician assessment, 4) pain visual analogue
scale, and 5) disability and functional scale. ACR 20
is suggestive of 20% improvement in the number of
tender and swollen joints and 20% improvement in
any three out of 5 constituents mentioned above.
This criterion is used to determine treatment efﬁcacy in mitigating manifestations of rheumatoid
arthritis. ACR 20 criteria was discovered by Dr.
Daniel Aletaha, consultant physician of rheumatology in Medical University of Vienna, Austria.

3.11. ACR 50 criterion
This criterion is used to assess the improvement
in the number of tender and swollen joints and
improvement in three out of ﬁve constituents 1)
acute phase reactants, 2) patient global assessment,
3) physician assessment, 4) pain visual analogue
scale, and 5) disability and functional scale. ACR 50
is suggestive of 50% improvement in numbers of
tender and swollen joints and 50% improvement in
any three out of 5 constituents mentioned above.
This criterion is used to determine treatment efﬁcacy in mitigating manifestations of rheumatoid
arthritis. ACR 50 criteria was also discovered by Dr.
Daniel Aletaha.

4. Results
The mean age of patients included in the groups
was 46.69 ± 15.25 and 48.31 ± 13.37 years respectively, comprising 78.9% females in group A and
76.4% females in group B as shown in Table 1. Out
of the total study population of 246 individuals, 67
were diabetic and 79 were hypertensive. While
another 39 participants reported a history of skipped
dosages of MTX due to side effects, however, statistically insigniﬁcant among the study groups.
Frequency of side effects reported by each group
is presented in Fig. 2. The most frequently reported
side effect was decreased appetite, followed by
gastritis, nausea, headache, and vomiting. After
splitting the dosage into two halves which were
administered to all the patients on alternate days
per week for six months in group B, a comparison
was done with group A (conventional once-weekly
dosage) amongst the baseline biochemical proﬁle
and disease activity scales. Mean corpuscular volume (MCV) was found to decrease in group B
(p ¼ 0.0128) after 6th month of therapy while rest of
the laboratory investigations were statistically
indifferent in both groups. Among the disease
severity scales, Within the two groups, pain
analogue scale, patient activity scales, and number
of tender joints were indifferent in alternate-day
regimen compared to conventional dosage. Also, no
signiﬁcant differences were found in the number of
swollen joints, physician and patient's global
assessment scores, SDAI, DAS-28 ESR, and CRP
scales as shown in Table 2.
Comparison of side effect proﬁle at 6 months after
intervention showed improved gastritis (63.4 vs
41.5%), nausea (51.2% vs 35.8%), appetite (74.0% vs
60.2%) and hepatotoxicity (14.6% vs 5.7%) in group
B. However, the incidence of gingival bleeding
increased with alternate-day dosage of MTX (10.5%

Table 1. Baseline characteristics of study participants (n ¼ 246).
Variables

Mean age
Gender

Frequency/Descriptives

Males
Females

Mean duration of
diagnosis (in years)
Diabetes
Hypertension
History of skipping dosage

MD/df

p-values

Group A
(n ¼ 123)

Group B
(n ¼ 123)

46.69 ± 15.25
n ¼ 26 (21.1%)
n ¼ 97 (78.9%)
7.11 ± 5.25

48.31 ± 13.37
n ¼ 29 (23.6%)
n ¼ 94 (76.4%)
6.29 ± 5.61

1.620
1

0.377a
0.646b

þ0.820

0.238a

38 (30.9%)
35 (28.4%)
24 (19.5%)

29 (23.5%)
44 (35.7%)
15 (12.2%)

1
1
1

0.197b
0.219b
0.116b

MD: mean difference; df: degrees of freedom.
a
Indicates student t-test.
b
Indicated chi-square test.

vs 22.0%) as shown in Table 3. In intention to treat
analysis, ACR 20 was achieved in 35% of individuals
in group A and 28% of individuals in group B, while
ACR 50 in 15% and 18% of groups respectively
(statistically indifferent).

5. Discussion
Once weekly regimen of MTX currently used
globally is optimum for the treatment of Rheumatoid
Arthritis until a large scale, long term and imperishable study is done to assess an alternative dosage
scheme.1 MTX's active compound i.e. polyglutamate
has a half-life of 3 days, hence with the usage of the

conventional one dose per week regimen drug levels
in the body would become suboptimal resulting in
poor efﬁcacy. However, previously regulated investigations revealed that regardless of the dosage
regimen MTX remains in the tissues for a long
duration.1 Another study compared the once-weekly
regimen with a split dosage of 22.5 mg/week MTX.
Astonishingly, results in both groups with regards to
treatment efﬁcacy and adverse effects incidence were
similar.2 In our study ﬁndings, alternate-day regimen
showed equal clinical efﬁcacy compared with conventional dosage accompanied by a signiﬁcantly
tolerable side effect proﬁle.

Fig. 2. Comparative frequency of side effects among study groups.
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Table 2. Comparison of disease activity and laboratory parameters among the study groups after 6 months.
Parameters

Group A

Group B

df

MD

p-value

Hemoglobin
Total leukocyte count
Platelet count
Mean corpuscular volume
Serum urea
Creatinine
ALT
CRP
ESR
Number of tender joints
Number of swollen joints
Patient's global assessment
Physician's global assessment
Pain analogue scale
Patient activity scale 1
Patient activity scale 2
SDAI
DAS 28 (ESR)
DAS 28 (CRP)

11.90 ± 1.86
10.24 ± 4.03
325.02 ± 107.39
85.07 ± 9.80
21.69 ± 7.73
0.70 ± 0.75
43.14 ± 13.73
7.67 ± 8.56
46.10 ± 24.48
8.60 ± 5.52
2.76 ± 3.05
5.75 ± 2.56
5.26 ± 1.90
7.46 ± 2.42
6.71 ± 2.52
6.65 ± 2.47
27.62 ± 11.45
5.31 ± 1.13
4.33 ± 1.05

12.24 ± 2.18
9.71 ± 3.69
299.46 ± 136.86
82.11 ± 8.69
23.36 ± 10.55
0.73 ± 0.98
37.75 ± 10.52
8.00 ± 8.39
47.88 ± 26.06
7.95 ± 4.21
2.54 ± 2.84
5.59 ± 2.40
5.16 ± 1.98
6.93 ± 2.44
6.46 ± 2.54
6.54 ± 2.46
28.08 ± 10.42
5.48 ± 1.18
4.25 ± 0.98

238.09
242.12
230.93
240.55
223.68
228.40
228.53
243.90
243.05
228.04
242.76
242.99
243.58
243.98
243.98
243.99
241.86
243.54
242.84

0.340
0.530
25.560
2.960
1.670
0.030
5.390
0.330
1.780
0.650
0.220
0.160
0.100
0.530
0.250
0.110
0.460
0.170
0.080

0.189
0.283
0.104
0.012*
0.158
0.787
0.001*
0.760
0.581
0.300
0.558
0.613
0.686
0.088
0.439
0.726
0.742
0.249
0.537

All p-values calculated by student's t-test (* indicates signiﬁcance of less than 0.05).
SDAI: Simple Disease Activity Index; ALT: Alanine transaminase; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; df:
degrees of freedom; MD: mean difference.

Previously conducted researches indicate that
amongst a population sample of patients consuming
MTX, gastric upset was present in (3.6e56.5%), followed by nausea (14.3e32%), stomach ache
(11.3e19.7%), vomiting (6.5e14.3%), hepatotoxicity
(8.6%), microbial infections (6.8%), anemia (5.7%),
joint pain (4.8%), elevated liver enzymes (4.3%),
Table 3. Comparison of side effects among the study groups after
intervention.
Sign/symptoms

Group A

Group B

p-value

Gastric upset/gastritis
Oral ulcers
Gingivitis
Nausea
Vomiting
Headache
Hair loss
Shortness of breath
Visual changes
Skin rash
Itching
Gingival bleeding
Decreased appetite
Diarrhea
Infertility
Abortion
Orthostatic hypotension
Convulsions
Eye redness
Photosensitivity
Hepatotoxicity
Others

78 (63.4%)
30 (24.4%)
7 (5.7%)
63 (51.2%)
50 (40.7%)
58 (47.1%)
40 (32.5%)
34 (27.6%)
9 (7.3%)
20 (16.3%)
15 (12.2%)
13 (10.5%)
91 (74.0%)
18 (14.6%)
3 (2.4%)
1 (0.8%)
1 (0.8%)
1 (0.8%)
2 (1.6%)
12 (9.7%)
18 (14.6%)
14 (11.4%)

51 (41.5%)
24 (19.5%)
8 (6.5%)
44 (35.8%)
39 (31.7%)
44 (35.8%)
37 (30.1%)
38 (30.9%)
11 (8.9%)
17 (13.8%)
14 (11.4)
27 (22.0%)
74 (60.2%)
15 (12.2%)
3 (2.4%)
0 (0.0%)
1 (0.8%)
1 (0.8%)
1 (0.8%)
16 (13.0%)
7 (5.7%)
10 (8.1%)

0.001a
0.461a
0.774a
0.018a
0.148a
0.087a
0.788a
0.724a
0.804a
0.743a
1.000a
0.038a
0.036a
0.720a
1.000b
1.000b
1.000b
1.000b
1.000b
0.125a
0.001a
0.125a

a
b

Indicates Chi-square test.
Indicates Fisher's exact test.

thrombocytopenia (2.1%), stomatitis (2.0e2.1%),
pneumonitis (2.2%), pulmonary Tuberculosis (2.2%),
leucopenia (1.4e2.2%), nephrotoxicity (2.1%),
pancytopenia (1.4%), hair loss (0.5e1.4%), breathing
problems (1.4%), visual problems (1.4%), headache
(0.7%) and skin rashes in (0.2%) of patients,
respectively.4,11,17e20 Other adverse reactions
include gingivitis, anorexia, diarrhea, hematemesis,
melena, enteritis, pancreatitis, lymphadenopathy,
pericardial effusion, hypotension, increased risk of
thromboembolic events, aphasia, hemiparesis,
convulsion, stress fractures, conjunctivitis, pulmonary ﬁbrosis, pruritus, photosensitivity, erythema
multiforme, dermatitis, renal dysfunction, azotemia,
cystitis, hematuria, oliguria, vaginal discharge, gynecomastia, infertility, abortion, fetal defects,
vasculitis, impotence, diabetes, osteoporosis, osteonecrosis of bone, tumor lysis syndrome, anaphylactic reactions, transaminitis, interstitial lung
disease, oral ulcers, and opportunistic infections.
Dhaon P, et al. and Luis M, et al. in their respective researches assessed disease activity by SDAI
score in the range of 0e86.3,9 While Luis M, et al.
reported every other week regimen was associated
with less hepatotoxicity but disease activity showed
remission equally with once-weekly dosage.9 We
reported an improved side effect proﬁle including
liver enzymes. Dhaon P, et al. rendered oral split
dosage more effective than once-weekly regimen by
improving SDAI but adverse effects were not
different in both the groups. Moreover, 13% of patients discontinued the treatment due to adverse

events.3 In the current study, SDAI was not different
in both the groups however, pain visual analogue
scale and patient activity scale showed improvement. Pandya S, et al. also reported a decreased
number of tender joints with split weekly dosage,
similar to our ﬁndings.1 On patients with long-term
treatment schedules, shifting dosage from oral to
subcutaneous (SC) or starting the regimen with SC
route is more potent and likely to improve treatment
efﬁcacy.7 If treatment outcome is not adequate then
combination therapy with MTX is recommended.7
One study proposed that a split dosage of oral as
well as parenteral MTX is more potent and effective
than a single dose.9 Drug bioavailability signiﬁcantly improves when patients use the split dosage
modality of MTX rather than a single oral dose.3
In patients suffering from psoriasis, hepatotoxicity is
noted with increased administration of MTX.1 Also, no
tangible difference is reported in alanine transaminase
and aspartate transaminase levels for patients who are
on weekly versus every other week MTX dosage.1
Parenteral delivery of MTX is avowed for reducing
gastrointestinal (GI) adverse events but it is usually
known for creating greater overall side effects
compared to the oral route.2 In one study it was
revealed that 13 patients out of 20 were changed from
oral to parenteral route administration due to
increased GI adverse effects.2 Dhaon, et al. suggested
that GI side effects came out to be similar with onceweekly oral vs subcutaneous MTX regimen.3 Patients
who are already on once-weekly dosage can be easily
shifted to every other week dosing regimen without
experiencing a ﬂicker in their disease activity.11
Another study reported adverse events rate of 58%.
Amongst whom 60% of patients were on standard
dosage (15 mg/week), while 56% of the patients were
consuming larger doses of (25 mg/week), respectively.16 MTX administration for 3 days in a row can
result in sepsis and ultimately death.8
There were certain limitations of the current study
including observed and unobserved confounders,
lack of randomization, and internal validity. The efﬁcacy of an alternate regimen cannot be predicted
with this study design, it confers a randomized control trial to compare efﬁcacy. The major limitation
included there was no actual controlling for dosage
of MTX in our study among the study groups.
However, the beneﬁcial observations of improved
side effect proﬁles have been reported successfully.

6. Conclusions
The side effect proﬁle of MTX may be one of the
reasons for the patient's non-compliance with the
therapy. An alternate-day regimen may be more
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beneﬁcial for the patient's compliance due to fewer
side effects and similar efﬁcacy to the conventional
dosage reported in the current study. This approach
can be associated with less GI involvement by the
drug, more compliance with the regimen, and a
tolerable dosage leading to favorable efﬁcacy towards their current disease activity.
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